Cost effectiveness of palivizumab in Spain: an analysis using observational data. (Q33517462)

27 July 2017

title

Cost effectiveness of palivizumab in Spain: an analysis using observational data. (English)

1 reference

cost-effectiveness analysis

27 July 2017

main subject

1 reference

Mark J Nuijten

1

1 reference

27 July 2017

Wolfgang Wittenberg

series ordinal

2

1 reference

27 July 2017

publication date

5 December 2009

1 reference

The European Journal of Health Economics

27 July 2017

published in

1 reference

27 July 2017

volume

11

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

105-115

1 reference

https://scigraph.springernature.com/pub.10.1007/s10198-009-0206-x

27 July 2017

exact match

0 references

cites work

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Respiratory syncytial virus infection

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

The selection of data sources for use in modelling studies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10198-009-0206-X

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10198-009-0206-X

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2816247

[Cost effectiveness analysis in health]

31 October 2018

1 reference

12 December 2020

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Thresholds in cost-effectiveness analysis--more of the story

1 reference

12 December 2020

[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]

1 reference

12 December 2020

Recommendations for the prevention of respiratory syncytial virus infections. Standards Committee of the Spanish Society of Neonatology. Board of Directors of the Spanish Society of Neonatology

1 reference

12 December 2020

10.1007/S10198-009-0206-X

Identifiers

DOI

1 reference

27 July 2017

1 reference

27 July 2017

1 reference